RxDoctor Payments Data

David Konstandt, MD

Urology · Mooresville, NCNPI 1881670164

Payments from drug & device makers

$4,393in general payments, 2019–2025

Across 79 payments — averaging $55.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Scientific Affairs, LLC$2K
  • Astellas Pharma US Inc$557
  • Dendreon Pharmaceuticals LLC$530
  • C. R. Bard, Inc. & Subsidiaries$400
  • Boston Scientific$207
  • Medtronic$197
  • plus $988 from 23 others
$710in research payments, 2019–2025

Across 1 payment — averaging $710.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$710

What the payments were for

  • Consulting fees$2,41555%
  • Food & beverage$1,80841%
  • Education$1704%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,393 in reported general payments places this provider in the 60th percentile of 434 urology providers in North Carolina.

See all urology providers in North Carolina

Medicare billing

Part B allowed, 2024
$601,803
Medicare patients
845
Services billed
12,565

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide73$1,040,075
OrgovyxRelugolix228$603,353
NubeqaDarolutamide12$167,068
MyrbetriqMirabegron86$79,317
GemtesaVibegron49$42,544
ElmironPentosan Polysulfate Sodium15$13,950
Tamsulosin Hcl390$4,714
Silodosin29$2,517
Finasteride195$2,314
Solifenacin Succinate23$2,110
NitrofurantoinNitrofurantoin Macrocrystal38$1,453
Potassium Citrate ErPotassium Citrate20$1,360
Alfuzosin Hcl ErAlfuzosin Hcl55$1,321
Cephalexin111$1,260
Bicalutamide30$1,062

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$557$1,119,392159 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$93$645,897277 claims
BayerNubeqa$47$167,06812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 434 urology providers in North Carolina.

Other urology in Mooresville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →